New weight loss pill MWN109 enters first human safety trial
NCT ID NCT06938269
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new tablet called MWN109 in healthy adults who are overweight or have obesity. The main goal is to check if the drug is safe and how the body processes it. About 60 participants will receive either the drug or a placebo, and researchers will monitor side effects and lab results. This is a first step to see if the drug might help with weight management in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMAX Clinical Research
RECRUITINGAdelaide, South Australia, 5000, Australia
-
Veritus Research
NOT_YET_RECRUITINGBayswater, Victoria, 3153, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection help tackle obesity and diabetes? a safety trial begins
- Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test.
- App sends mindfulness exercises right after weight regain to keep dieters on track
- Sleep program aims to reduce pregnancy risks in african american women
- Could a Muscle-Building drug boost weight loss? new trial tests bimagrumab with semaglutide
- Weekly shot could help shed pounds in obesity trial